๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tianjin
Clinical trial register · China

Clinical Trials in Tianjin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 36 Beijing 20 Guangzhou 11 Tianjin 11 Jinan 6
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai36 Beijing20 Guangzhou11 Tianjin11 Jinan6
All 24 locations
Target enrolment
to

Trials with a site in Tianjin

11 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Phase I Study of HRS-3005 in B-cell Malignancies
NCT07556822B-cell Malignancy
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
190
Tianjin
2026-06-03
Recruiting
A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
NCT07407283Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
100
Chengdu, Tianjin
2026-04-08
Recruiting
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
NCT07230106Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
218
Nanjing, Tianjin
2025-12-08
Recruiting
A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
NCT07189949Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
120
Tianjin
2025-10-16
Recruiting
A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
NCT07136142Malignant Solid Tumor
DrugFH-006
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
150
Shanghai, Tianjin
2025-09-23
Recruiting
A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors
NCT07070349Patients With Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
48
Tianjin
2025-07-10
Recruiting
A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer
NCT06974929Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
80
Tianjin
2025-05-22
Active, closed
A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
NCT06126640HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
1,615
Shanghai, Tianjin
2023-11-20
Recruiting
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
NCT05884255Advanced Gastroenteropancreatic Neuroendocrine Tumor
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
220
Shanghai, Tianjin
2023-07-06
Active, closed
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
NCT04639180Hepatocellular Carcinoma (HCC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
687
Chongqing, Nanjin, Guiyang, Shanghai, Tianjin
2021-04-01
Active, closed
Extension Study of Hetrombopag in Severe Aplastic Anemia
NCT04961710Treatment-naive Severe Aplastic Anemia
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
157
Tianjin
2019-09-19
Rows per page Showing 1–11 of 11
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/tianjin

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 11 of those studies with a site in Tianjin that also match the filters currently applied.

How many clinical trials are recruiting in Tianjin?

8 of the 11 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Tianjin), 11 studies
PhaseStudiesRecruitingShare
Phase 1/24436.4%
Phase 34136.4%
Phase 12218.2%
Phase 2119.1%

Most active sponsors

Lead sponsors with the most studies (Tianjin)
Lead sponsorStudiesRecruiting
Jiangsu HengRui Medicine Co., Ltd.118
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.